Citations

Showing 10 of 108162 citations.

Maintaining intravenous volume mitigates hypothermia‐induced myocardial dysfunction and accumulation of intracellular Ca2+
Nilsen, Jan Harald, Schanche, Torstein , Kondratiev, Timofei, Hevrøy, Olav, Sieck, Gary C. , Tveita, Torkjel , Sieck, Gary

Mayo Clinic

Experimental Physiology | March 17, 2021 | Volume: 106 | Issue: 5 | Pages: 1196-1207

10.1113/ep089397 | PMID 33728692 Get It

New Findings What is the central question of this study? Detailed guidelines for volume replacement to counteract hypothermia‐induced intravascular fluid loss are lacking. Evidence suggests colloids might have beneficial effects compared to crystalloids. Are central haemodynamic function and level of hypothermia‐induced calcium overload, as a marker of cardiac injury, restored by fluid substitution during rewarming, and are colloids favourable to crystalloids? What is the main finding and its importance? Infusion with crystalloid or dextran during rewarming abolished post‐hypothermic cardiac dysfunction, and partially mitigated myocardial calcium overload. The effects of volume replacement to support haemodynamic function are comparable to those using potent cardio‐active drugs. These findings underline the importance of applying intravascular volume replacement to maintain euvolaemia during rewarming. AbstractPrevious research exploring pathophysiological mechanisms underlying circulatory collapse after rewarming victims of severe accidental hypothermia has documented post‐hypothermic cardiac dysfunction and hypothermia‐induced elevation of intracellular Ca2+ concentration ([Ca2+]i) in myocardial cells. The aim of the present study was to examine if maintaining euvolaemia during rewarming mitigates cardiac dysfunction and/or normalizes elevated myocardial [Ca2+]i. A total of 21 male Wistar rats (300 g) were surface cooled to 15°C, then maintained at 15°C for 4 h, and subsequently rewarmed to 37°C. The rats were randomly assigned to one of three groups: (1) non‐intervention control (n = 7), (2) dextran treated (i.v. 12 ml/kg dextran 70; n = 7), or (3) crystalloid treated (24 ml/kg 0.9% i.v. saline; n = 7). Infusions occurred during the first 30 min of rewarming. Arterial blood pressure, stroke volume (SV), cardiac output (CO), contractility (dP/dtmax) and blood gas changes were measured. Post‐hypothermic changes in [Ca2+]i were measured using the method of radiolabelled Ca2+ (45Ca2+). Untreated controls displayed post‐hypothermic cardiac dysfunction with significantly reduced CO, SV and dP/dtmax. In contrast, rats receiving crystalloid or dextran treatment showed a return to pre‐hypothermic control levels of CO and SV after rewarming, with the dextran group displaying significantly better amelioration of post‐hypothermic cardiac dysfunction than the crystalloid group. Compared to the post‐hypothermic increase in myocardial [Ca2+]i in non‐treated controls, [Ca2+]i values with crystalloid and dextran did not increase to the same extent after rewarming. Volume replacement with crystalloid or dextran during rewarming abolishes post‐hypothermic cardiac dysfunction, and partially mitigates the hypothermia‐induced elevation of [Ca2+]i.
Sex differences in CSF biomarkers for neurodegeneration and blood‐brain barrier integrity
Blennow, Kaj , Machado, Alejandra , Pereira, Joana B. , Lindberg, Olof , Zettergren, Anna , Rydén, Lina , Westman, Eric , Kern, Silke , Westman, Eric , Skillbäck, Tobias Borgh , Zetterberg, Henrik , Shams, Sara , Mielke, Michelle M. , Wahlund, Lars‐Olof , Skoog, Ingmar

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | March 17, 2021 | Volume: 13 | Issue: 1 | Pages: No page available

10.1002/dad2.12141 | PMID 33748393 Get It

Abstract Introduction As cerebrospinal fluid (CSF) neurofilament light protein (NfL) and the CSF/serum albumin ratio (Q Alb ) are used in the clinical routine, the impact of demographic factors on these biomarkers is important to understand. Methods Participants were derived from two Swedish samples: the population‐based H70 Study (n = 308, age 70) and a clinical routine cohort (CSF NfL, n = 8995, Q Alb , n = 39252, age 0 to 95). In the population‐based study, Q Alb and NfL were examined in relation to sex, cardiovascular risk factors, and cerebral white matter lesions (WMLs). In the clinical cohort, Q Alb and NfL sex differences were tested in relation to age. Results Men had higher Q Alb and NfL concentrations and had higher Q Alb and NfL concentrations from adolescence throughout life. NfL was not related to WML, but Q Alb correlated positively with WMLs. Discussion The CSF NfL sex difference could not be explained by vascular pathology. Future studies should consider using different reference limits for men and women.
Integrating Genomic Screening into Primary Care: Provider Experiences Caring for Latino Patients at a Community-Based Health Center
Srinivasan, Tarika , Sutton, Erica J., Beck, Annika T., Cuellar, Idali, Hernandez, Valentina, Pacyna, Joel E. , Shaibi, Gabriel Q. , Lindor, Noralane M. , Sharp, Richard R. , Sharp, Richard R , Kullo, Iftikhar J. , Singh, Davinder

Mayo Clinic

Journal of Primary Care & Community Health | March 17, 2021 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/21501327211000242 | PMID 33729042 Get It

Introduction: Minority communities have had limited access to advances in genomic medicine. Mayo Clinic and Mountain Park Health Center, a Federally Qualified Health Center in Phoenix, Arizona, partnered to assess the feasibility of offering genomic screening to Latino patients receiving care at a community-based health center. We examined primary care provider (PCP) experiences reporting genomic screening results and integrating those results into patient care. Methods: We conducted open-ended, semi-structured interviews with PCPs and other members of the health care team charged with supporting patients who received positive genomic screening results. Interviews were recorded, transcribed, and analyzed thematically. Results: Of the 500 patients who pursued genomic screening, 10 received results indicating a genetic variant that warranted clinical management. PCPs felt genomic screening was valuable to patients and their families, and that genomic research should strive to include underrepresented minorities. Providers identified multiple challenges integrating genomic sequencing into patient care, including difficulties maintaining patient contact over time; arranging follow-up medical care; and managing results in an environment with limited genetics expertise. Providers also reflected on the ethics of offering genomic sequencing to patients who may not be able to pursue diagnostic testing or follow-up care due to financial constraints. Conclusions: Our results highlight the potential benefits and challenges of bringing advances in precision medicine to community-based health centers serving under-resourced populations. By proactively considering patient support needs, and identifying financial assistance programs and patient-referral mechanisms to support patients who may need specialized medical care, PCPs and other health care providers can help to ensure that precision medicine lives up to its full potential as a tool for improving patient care.
Cannulation strategies & circulation management in type‐A aortic dissection
Saran, Nishant , Pochettino, Alberto

Mayo Clinic

Journal of Cardiac Surgery | March 17, 2021 | Volume: 36 | Issue: 5 | Pages: 1793-1798

10.1111/jocs.15456 | PMID 33728710 Get It

Mechanotransduction in gastrointestinal smooth muscle cells: role of mechanosensitive ion channels
Joshi, Vikram , Strege, Peter R. , Farrugia, Gianrico , Strege, Peter R , Beyder, Arthur , Joshi, Vikram

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | March 17, 2021 | Volume: 320 | Issue: 5 | Pages: G897-G906

10.1152/ajpgi.00481.2020 | PMID 33729004 Get It

Mechanosensation, the ability to properly sense mechanical stimuli and transduce them into physiologic responses, is an essential determinant of gastrointestinal (GI) function. Abnormalities in this process result in highly prevalent GI functional and motility disorders. In the GI tract, several cell types sense mechanical forces and transduce them into electrical signals, which elicit specific cellular responses. Some mechanosensitive cells like sensory neurons act as specialized mechanosensitive cells that detect forces and transduce signals into tissue-level physiological reactions. Nonspecialized mechanosensitive cells like smooth muscle cells (SMCs) adjust their function in response to forces. Mechanosensitive cells use various mechanoreceptors and mechanotransducers. Mechanoreceptors detect and convert force into electrical and biochemical signals, and mechanotransducers amplify and direct mechanoreceptor responses. Mechanoreceptors and mechanotransducers include ion channels, specialized cytoskeletal proteins, cell junction molecules, and G protein-coupled receptors. SMCs are particularly important due to their role as final effectors for motor function. Myogenic reflex—the ability of smooth muscle to contract in response to stretch rapidly—is a critical smooth muscle function. Such rapid mechanotransduction responses rely on mechano-gated and mechanosensitive ion channels, which alter their ion pores’ opening in response to force, allowing fast electrical and Ca 2+ responses. Although GI SMCs express a variety of such ion channels, their identities remain unknown. Recent advancements in electrophysiological, genetic, in vivo imaging, and multi-omic technologies broaden our understanding of how SMC mechano-gated and mechanosensitive ion channels regulate GI functions. This review discusses GI SMC mechanosensitivity's current developments with a particular emphasis on mechano-gated and mechanosensitive ion channels.
Oral mini‐pulse therapy in vitiligo: a systematic review
Chávez‐Álvarez, Sonia , Raygoza‐Cortez, Ana Karina, Suro‐Santos, Yeudiel , Álvarez‐Villalobos, Neri Alejandro , Villarreal‐Martínez, Alejandra , Raygoza-Cortez, Karina , Raygoza-Cortez, Ana Karina, Alvarez-Villalobos, Neri Alejandro, Álvarez-Villalobos, Neri A , Herz‐Ruelas, Maira Elizabeth , Ocampo‐Candiani, Jorge

Mayo Clinic

International Journal of Dermatology | March 17, 2021 | Volume: 60 | Issue: 7 | Pages: 868-876

10.1111/ijd.15464 | PMID 33729554 Get It

Abstract Background There is limited evidence supporting the use of alternative treatments for patients with nonstable vitiligo. Objective This study aimed to review the effects of oral mini‐pulse (OMP) therapy in the management of nonsegmental vitiligo. Methods The following databases were searched between inception and May 2020 for relevant studies: Scopus, Web of Science, MEDLINE, and Embase. All randomized controlled trials that compared OMP therapy with any other active treatment or placebo for nonstable vitiligo were included. The Cochrane’s risk of bias tool was used to evaluate the risk of bias (ROB) in selected studies, and the overall quality of evidence of each outcome was assessed using the Grading Recommendations, Assessment, Development, and Evaluations (GRADE) system. Results Four studies met our selection criteria. All of them were conducted in India and included 246 patients. OMP therapy included betamethasone or dexamethasone. The duration of treatment was 6 months in all studies. Up to 32% of patients achieved a repigmentation rate of >75% when OMP therapy was administered as monotherapy. No difference was observed between OMP therapy and other treatments in arresting the disease, and weight gain was the most frequent adverse effect. The overall ROB in all included studies was relatively high because of the randomization process, outcome measurement and informed selection of outcomes. Conclusion Based on the findings of these studies, OMP therapy did not demonstrate additional value compared with other treatments. Hence, there is an urgent need to conduct high‐quality clinical trials to evaluate this therapy.
Gender and authorship trends in rhinology, allergy, and skull‐base literature from 2008 to 2018
Halderman, Ashleigh A. , Rao, Anupriya, Desai‐Markowski, Stuti, Yang, Alex , Luong, Amber , O’Brien, Erin K. , Gray, Stacey T. , Lal, Devyani , Lin, Sandra Y. , Orlandi, Richard R. , Wise, Sarah K. , O'Brien, Erin K , Orlandi, Richard , Lal, Devyani

Mayo Clinic

International Forum of Allergy & Rhinology | March 17, 2021 | Volume: 11 | Issue: 9 | Pages: 1336-1346

10.1002/alr.22793 | PMID 33728798 Get It

BackgroundA recent analysis suggested potential narrowing of the gender gap in research productivity in the field of rhinology. This analysis did not, however, provide insight into how the genders are represented in the rhinologic literature. This study aimed to evaluate 11 years of literature to evaluate for gender differences in authorship position, collaborations, category and content of research, citations, and funding to gain perspective on how gender and authorship has changed over time.MethodsAuthorship data for all articles on rhinologic subject matter published between January 1, 2008 and December 31, 2018 in four otolaryngology journals was collected. The gender of authors was determined by protocol. Category and content of research and funding status/source were additionally obtained.ResultsData were collected from 2666 articles. Gender of 14,510 authors was determined. Female authors accounted for 23% of the overall authors and male authors accounted for 77%. Female first authorship increased significantly over time, but there was no change in female senior authorship. The percentage of female authors steadily increased over time, whereas male authorship decreased slightly. Mixed gender teams were shown to be increasing in frequency. Women published more than expected in basic science and allergy and less than expected in skull base. On funded studies, women were significantly underrepresented as senior authors.ConclusionThis study represents the first assessment of gender differences in the rhinology literature. Areas where female representation can improve include senior authorship, increased involvement in skull base publications, and increased funding.
Sustained Release GLP‑1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson’s Disease
Wang, Vicki, Kuo, Tung‐Tai , Huang, Eagle Yi-Kung, Ma, Kuo-Hsing, Fu, Zhao-Yang, Lai, Li-Wen, Jung, Jin Ho , Choi, Hoi-II, Choi, Doo‐Sup , Li, Yazhou , Olson, Lars, Hoffer, Barry J. , Choi, Doo-Sup , Huang, Eagle Yi‐Kung, Ma, Kuo‐Hsing , Chou, Yu‐Ching , Olson, Lars, Greig, Nigel H. , Chen, Yuan-Hao

Mayo Clinic

ACS Pharmacology & Translational Science | March 17, 2021 | Volume: 4 | Issue: 2 | Pages: 858-869

10.1021/acsptsci.1c00013 | PMID 33860208 Get It

Abstract GLP-1 agonists have become increasingly interesting as a new Parkinson’s disease (PD) clinical treatment strategy. Additional preclinical studies are important to validate this approach and define the disease stage when they are most effective. We hence characterized the efficacy of PT320, a sustained release formulation of the long acting GLP-1 agonist, exenatide, in a progressive PD (MitoPark) mouse model. A clinically translatable biweekly PT320 dose was administered starting at 5 weeks of age and longitudinally evaluated to 24 weeks, and multiple behavioral/cellular parameters were measured. PT320 significantly improved spontaneous locomotor activity and rearing in MitoPark PD mice. “Motivated” behavior also improved, evaluated by accelerating rotarod performance. Behavioral improvement was correlated with enhanced cellular and molecular indices of dopamine (DA) midbrain function. Fast scan cyclic voltammetry demonstrated protection of striatal and nucleus accumbens DA release and reuptake in PT320 treated MitoPark mice. Positron emission tomography showed protection of striatal DA fibers and tyrosine hydroxylase protein expression was augmented by PT320 administration. Early PT320 treatment may hence provide an important neuroprotective therapeutic strategy in PD.
Pulmonary hypertension due to interstitial lung disease or chronic obstructive pulmonary disease: a patient experience study of symptoms and their impact on quality of life
DuBrock, Hilary M. , Nathan, Steven D. , Mathai, Stephen C. , Classi, Peter, Nelsen, Andrew C. , Olayinka‐Amao, Bimpe, Norcross, Lindsey , Martin, Susan , Martin, Susan A , DuBrock, Hilary M , Mathai, Stephen C , Reeve, Bryce B. , Kolaitis, Nicholas A

Mayo Clinic

Pulmonary Circulation | March 16, 2021 | Volume: 11 | Issue: 2 | Pages: 1-9

10.1177/20458940211005641 | PMID 33868642 Get It

Pulmonary hypertension resulting from chronic lung disease such as chronic obstructive pulmonary disease and interstitial lung disease is categorized by the World Health Organization as Group 3 pulmonary hypertension. To identify the symptoms and impacts of World Health Organization Group 3 pulmonary hypertension and to capture data related to the patient experience of this disease, qualitative research interviews were undertaken with 3 clinical experts and 14 individuals with pulmonary hypertension secondary to chronic obstructive pulmonary disease or interstitial lung disease. Shortness of breath, fatigue, cough, and swelling were the most frequently reported symptoms of pulmonary hypertension due to chronic obstructive pulmonary disease or interstitial lung disease, and shortness of breath was further identified as the single most bothersome symptom for most patients (71.4%). Interview participants also described experiencing a number of impacts related to pulmonary hypertension and pulmonary hypertension symptoms, including limitations in the ability to perform activities of daily living and impacts on physical functioning, family life, and social life as well as emotional impacts, which included frustration, depression, anxiety, isolation, and sadness. Results of these qualitative interviews offer an understanding of the patient experience of pulmonary hypertension due to chronic obstructive pulmonary disease or interstitial lung disease, including insight into the symptoms and impacts that are most important to patients in this population. As such, these results may help guide priorities in clinical treatment and assist researchers in their selection of patient‐reported outcome measures for clinical trials in patients with pulmonary hypertension due to chronic obstructive pulmonary disease or interstitial lung disease.